Idiopathic epiretinal membranes (iERMs) are fibrocellular sheets of tissue that develop on the vitreoretinal interface of the eye. When located in front of the fovea and having a retracting behavior, they generate a clinical condition known as macular pucker, which disrupts the underlying retinal architecture strongly affecting visual capacity.[@bib1]

Components of iERMs are cells and extracellular matrix. As far as cells are concerned, it is still not clear which cell lineage they derive from. Ultrastructural and immunocytochemical investigations based on the expression of specific cell markers have pointed to hyalocytes, Müller cells, astrocytes, fibroblasts, and retinal pigmented epithelial cells as the ultimate source of epiretinal membrane (ERM) cells.[@bib2]^--^[@bib4] When considering iERMs, molecular markers appear mixed up probably because of an ongoing process of transdifferentiation. Thus for instance, coexpression of glial fibrillary acidic protein (GFAP) with hyalocyte markers has been reported,[@bib4]^,^[@bib5] and α-smooth muscle actin (αSMA) is a constant finding even though cells that supposedly generate ERMs do not express it in a resting state. Whichever the cell type of origin is, de novo expression of αSMA likely testifies a transdifferentiation progression toward a myofibroblastic phenotype.[@bib4]^,^[@bib6]^--^[@bib9] Transdifferentiation into myofibroblast-like cells is probably the key event for the production of collagen proteins and for the generation of the force required for ERM retraction.[@bib9]^,^[@bib10] Interestingly, αSMA can be expressed by cells derived from retinal pigment epithelial cells and hyalocytes, respectively, after a process of epithelial-mesenchymal transition or transdifferentiation,[@bib4]^,^[@bib11]^,^[@bib12] and by Müller cells[@bib13]^,^[@bib14] after a process of glial-mesenchymal transition.[@bib15] In practice, all cell types that have been proposed to give rise to ERM cells can transdifferentiate into a myofibroblast-like phenotype because reactive astrocytes can also express αSMA.[@bib16]

ERMs contain variable amounts of extracellular matrix. Components of the extracellular matrix identified so far include type-I to VI collagens, heparan sulfate proteoglycans, laminin, fibronectin, tenascin, and decorin.[@bib4]^,^[@bib17]^--^[@bib22] Hence ERMs have the major hallmarks of fibrotic disorders as they show an exuberant deposition of extracellular matrix and/or the development of a retracted fibrotic scar tissue, which eventually disrupts organ architecture and function.[@bib23] Molecules mediating fibrosis are numerous and some of them have been found in ERMs as well. Transforming growth factor-β (TGF-β) is one of them, as immunohistochemistry demonstrated the expression of both TGF-β1 and its receptor in cells of iERMs.[@bib7] TGF-β1 binding to type-II TGF-β receptor (TβRII) activates type-I TGF-β receptor, which in turn triggers SMAD-dependent and SMAD-independent signal transduction pathways.[@bib24] Both pathways eventually promote transcription of TGF-β target genes that are needed for fibrogenesis. SMAD proteins are cytoplasmic mediators of the canonical TGF-β signal pathway. Activation of the SMAD-dependent pathway requires SMAD2 and SMAD3 phosphorylation. Once phosphorylated, SMAD 2/3 binds to SMAD4 and move to the nucleus to regulate gene expression including *COL1A1* (type-I collagen).[@bib25] TGF-β1 signaling pathway can be modulated by numerous molecules, one of them being the 90-kDa heat shock protein (HSP90). HSP90 is a family of proteins that act as chaperones for several client proteins. Their role in fibrotic disorders has been shown in a number of experimental contexts employing specific inhibitors.[@bib26]^--^[@bib28] As the use of HSP90 inhibitors is a promising therapeutic approach for fibrosis[@bib29]; HSP90 is currently the focus of intense research. Here we report that HSP90α can be found in samples of iERMs and that its expression appears to be correlated with the presence of TβRII and αSMA. Because there are evidences that at least part of ERM cells may derive from Müller cells,[@bib9]^,^[@bib21] we also explored the mechanisms underlying HSP90 modulation of the TGF-β1-induced transduction pathway in MIO-M1 cells, a spontaneously immortalized human Müller cell line.[@bib13]

Materials and Methods {#sec2}
=====================

Patients and Samples {#sec2-1}
--------------------

Patients affected by iERMs were subjected to primary 25-gauge pars plana vitrectomy (PPV) by the same surgeon (GMT) without intraocular complications between January 2014 and August 2017 at the Ophthalmology Section of Siena University Hospital, Siena, Italy. The exclusion criteria were diabetes mellitus, coexisting ocular disorders, except cataract; patients requiring PPV for indications other than those mentioned earlier; and patients previously subjected to intraocular surgery, except cataract surgery. The research adhered to the principles of the Declaration of Helsinki, and the institutional review board approved the study. Patients were treated after being informed of the nature of the treatment being offered, its potential risks, benefits, adverse effects, possible outcomes, and after having signed a consent form. ERMs were stained based on surgeon preference and were excised using a Grieshaber Revolution forceps (Alcon Laboratories Inc., Fort Worth, TX, USA). ERM peeling was always started from the edge of the macula. Fluid/air exchange was performed in every patient at the end of the procedure. In cases with coexisting cataract, phacoemulsification and intraocular lens implantation was performed before vitrectomy through a corneal incision.

A total number of 36 iERMs, 15 of them associated with the internal limiting membrane (ILM), were included in this study, and processed as follows. Membranes were fixed with 1.25% glutaraldehyde in 0.1 M sodium cacodylate for 24 hours at 4°C and postfixed in 1% OsO~4~ for 2 hours at 4°C. After fixation, samples were dehydrated and embedded in Epon following standard procedures. Semithin sections (1-µm thick), cut from each block of resin with an ultramicrotome Ultrotome Nova (LKB, Bromma, Sweden), were placed on well-degreased slides.

Five additional iERMs were sampled between September and December 2019. They were embedded in OCT and frozen in isopentane prechilled with liquid nitrogen as previously reported.[@bib30] Seven-micrometer thick sections were cut and stored at --80°C until used for immunofluorescence experiments.

Antibodies {#sec2-2}
----------

The following primary antibodies were used: goat anti-αSMA (code SAB2500963), mouse anti-β-actin (code A5441), mouse anti-FLAG (code F-4042), and monoclonal mouse anti-vimentin (clone V9; code V6389) that were from Sigma-Aldrich (Saint Louis, MO, USA); rabbit anti-human GFAP (code 18-0063) and rabbit anti-human SMAD2 (code 51-1300) that were from Zymed (San Francisco, CA, USA); monoclonal mouse anti-GFAP (clone 6F2; code M0761) was purchased from DAKO (Glostrup, Denmark); rabbit anti-HSP90α (code MA3-010) was received from ThermoFisher (Rockford, IL); rabbit anti-human TβRII (code sc-220) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA); goat anti-vimentin was a kind gift from Peter Traub (Max-Plank Institut fur Zellbiologie, Rosenhof, Ladenburg, Germany)[@bib31]; rabbit anti-human type-I collagen was purchased from Novus Biologicals (Littleton, CO, USA), and goat anti-human type-IV collagen was obtained from SouthernBiotech (Birmingham, AL, USA); rabbit anti-phosphoSMAD2 (code 3108), anti-SMAD2 (code 5339), and anti-SMAD3 (code 9523) were purchased from Cell Signaling Technologies (Carlsbad, CA, USA); biotinylated rabbit anti-histone H3 (code NB500-171B) was received from Novus Biologicals LLC (Centennial, CO, USA).

The secondary antibodies, all double-labeling grade, were donkey tetramethylrhodamine (TRITC)-conjugated anti-goat IgG (code AP180R) from Chemicon (Temecula, CA, USA), donkey Cy2-conjugated F(ab')~2~ fragment anti-rabbit IgG (code 711-226-152), donkey Cy5-conjugated F(ab')~2~ fragment anti-rabbit IgG (code 711-176-152), and donkey Cy5-conjugated F(ab')~2~ fragment anti-mouse IgG (code 715-176-150) from Jackson ImmunoResearch Laboratories (West Grove, PA, USA).

Immunofluorescence and Confocal Microscopy {#sec2-3}
------------------------------------------

Confocal microscopy was carried out on semithin sections. Immunoreactions were performed on resin removal and antigen retrieval as previously reported.[@bib22] Positive immunoreactions were unveiled with the appropriate secondary antibodies conjugated with FITC or Cy2, TRITC, and Cy5. The combination of primary antibodies employed were the following: (1) goat anti-αSMA and rabbit anti-GFAP; (2) goat anti-αSMA, rabbit anti-GFAP, and mouse anti-vimentin; (3) rabbit anti-TβRII, goat anti-vimentin, and mouse anti-GFAP; (4) rabbit anti-TβRII, mouse anti-HSP90α, and goat anti-αSMA; (5) rabbit anti-GFAP, mouse anti-vimentin, and goat anti-αSMA; (6) goat anti-type IV collagen, rabbit anti-type I collagen, and mouse anti-vimentin; and (7) goat anti-αSMA, rabbit anti-type I collagen, and mouse anti-HSP90α. Once images were acquired with the confocal microscope to visualize cell nuclei, some experiments were continued, and the coverslips were gently removed. Antibodies were stripped incubating slides in 0.1 M glycine, pH 2.51, at 50°C for 30 minutes, and sections were reprobed overnight with biotin-conjugated anti-histone H3 antibody followed by Rhodamine Red-X-conjugated streptavidin (Jackson ImmunoResearch Laboratories). A clear nuclear staining was achieved, and new images were acquired on the previously spotted regions of interest. Images acquired exactly on the same microscopic fields (those with cytoplasmic labeling and those with the nuclear staining) were superimposed with Adobe Photoshop CS3 software (Adobe, San Jose, CA).

Expression of GFAP, αSMA, and vimentin was evaluated in all samples with the exception of three membranes that were too damaged to make a proper judgement over cell staining. In addition, TβRII expression, HSP90-immunoreactive cells, and type-I containing cells were assessed respectively in 17, 20, and 24 randomly chosen iERMs. Frozen sections were fixed in 10% buffered formalin, permeabilized with 0.1% Triton X-100 in PBS for 10 minutes and incubated overnight with the anti-SMAD2 antibody. After washing, sections were challenged with Cy2-conjugated anti-rabbit IgG, anti-HSP90α antibody, TRITC-conjugated anti-mouse IgG, and finally nuclei were counterstained with TO-PRO-3 iodide DNA dye (Invitrogen, Carlsbad, CA, USA).

Controls were carried out following the same earlier mentioned procedures with the exception of the primary antibodies that were replaced with PBS or with nonimmune serum from the same animal species employed to raise the antibodies.

Images were acquired with an LSM510 Zeiss (Carl Zeiss, Jena, Germany) confocal microscope with selective multitracking excitation.

Cell Culture, Lentiviral Particles Production, Cell Transduction, Whole Cell Extracts, and Immunoblotting {#sec2-4}
---------------------------------------------------------------------------------------------------------

Spontaneously immortalized human Müller glia cell line MIO-M1, kindly provided at passage \#15 by GA Limb from the Institute of Ophthalmology and Moorfield Eye Hospital (London, UK),[@bib13] was grown in Dulbecco\'s modified Eagle\'s medium containing high glucose and glutamine, and supplemented with 10% fetal bovine serum. Cells were amplified and frozen at passage \#17 for subsequent experiments. For each transduction experiment, cells were thawed and employed within passage \#19. Under normal culture conditions, MIO-M1 cells express markers of mature Müller cells, including cellular retinaldehyde binding protein, glutamine synthetase, vimentin, and epidermal growth factor receptor at least until passage \#45.[@bib13] Lentiviral particles production and cell transduction were performed as previously described[@bib32] with the following modifications: Lenti-X 293T (Takara Bio, Shiga, Japan) packaging cells were transiently transfected with the TransIT-VirusGEN Transfection Reagent (Mirus Bio LLC, Madison, WI, USA) following the manufacturer\'s instructions. MIO-M1 cells were transduced with lentiviral vectors for the expression of FLAG-tagged human HSP90 (Cat \#: RC218420L1; OriGene, Rockville, MD, USA) or the Green Fluorescent Protein (GFP) as negative control and control of infection efficiency. GFP and HSP90-FLAG transfected cells were treated with 1 ng/mL human recombinant TGF-β1 (Cat \#: 240-B; R&D Systems, Inc., Minneapolis, MN, USA) for the indicated time points (ranging from 2--24 hours), washed with PBS and lysed. Protein extracts and immunoblotting were performed as previously described.[@bib33] Western blot shown is representative of three separate experiments.

Results {#sec3}
=======

TβRII is Expressed in GFAP^−^/αSMA^+^/Vimentin^+^ ERM Cells {#sec3-1}
-----------------------------------------------------------

Semithin sections of iERMs were first labeled with antibodies to GFAP, αSMA, and vimentin, and results from these initial experiments are summarized in [Table 1](#tbl1){ref-type="table"}. GFAP-expressing cells were present in 78.8% of samples (26 iERMs), and were barely detectable in 9.1% of membranes (3 iERMs). GFAP was apparently absent in 12.1% of cases (4 iERMs). However, αSMA-expressing cells were found in 97% of samples (32 iERMs), and they were very few in 3% of cases (1 iERM). In contrast, vimentin was found in all iERMs and labeled virtually all cells. The ratio between αSMA^+^ and GFAP^+^ cells could be estimated only with good approximation. As summarized in [Table 2](#tbl2){ref-type="table"}, most iERMs (60.6% of samples) were characterized by a great majority of αSMA^+^ cells, whereas only one iERM was formed mainly by GFAP^+^ cells.

###### 

Cytoskeletal Marker Expression in iERMs

  Antibodies    Number of Tested Samples  Number of Samples with Positive Expression
  ------------ -------------------------- --------------------------------------------
  GFAP                     33             29 (78.8%)
  αSMA                     33             32 (97%)
  Vimentin                 33             33 (100%)

###### 

Number of iERMs with a Clear Prevalence of αSMA- or GFAP-Expressing Cells or with Approximatively a Comparable Number of Two Cell Types

  Antibodies    Number of Tested Samples   αSMA \> GFAP   αSMA = GFAP   αSMA \< GFAP
  ------------ -------------------------- -------------- ------------- --------------
  αSMA/GFAP                33               20 (60.6%)    12 (36.4%)       1 (3%)

Analysis in double and triple labeling experiments showed that αSMA- and GFAP-expressing cells were mostly different cells which, however, coexpressed vimentin as well ([Figs. 1](#fig1){ref-type="fig"}A--H). GFAP and αSMA, however, were not mutually exclusive molecular markers as a minor population of rare double labeled cells could be found in all samples provided with both GFAP- and αSMA-expressing cells ([Figs. 1](#fig1){ref-type="fig"}I--K). From the results of this set of experiments, we could infer that the great majority of all vimentin^+^/GFAP^−^ and vimentin^+^/αSMA^−^ cells were respectively αSMA-expressing and GFAP-expressing cells.

![Cytoskeletal markers expressed by cells in iERMs. (**A--C**) Differential expression of GFAP and αSMA in vimentin^+^ cells as assessed by confocal microscopy. Cell nuclei were labeled with anti-histone H3 antibody. (**D**) Bright-field microscopy of the same section employed in **A--C** and stained with toluidine blue demonstrates the general morphology of the ERM to which the ILM is associated. (**E--G**) Higher magnification of the framed area in **A--C**; vimentin immunoreactivity mostly colocalizes with αSMA (*yellowish color*). The intensity of the staining for αSMA, however, is variable. Instead of αSMA, some vimentin immunoreactivity colocalizes with GFAP (*arrow*). (**H**) Higher magnification of the framed area in **D**. The ILM is highlighted by arrowheads. (**I--K**) Some GFAP/αSMA double immunoreactivity can be also found (*yellow/orange colors*).](iovs-61-8-34-f001){#fig1}

Expression of TβRII was found in all tested iERMs but one (94.1% of cases). The number of positive cells was variable according to the sample. Triple labeling with anti-TβRII, anti-vimentin, and anti-GFAP antibodies showed that the receptor was mainly located in vimentin^+^/GFAP^−^ cells ([Figs. 2](#fig2){ref-type="fig"}A--H), which based on the previous consideration, should be considered mostly as αSMA^+^ cells. Also few vimentin^+^/GFAP^+^ cells, however, were labeled by the anti-TβRII antibody ([Figs. 2](#fig2){ref-type="fig"}A--D).

![TβRII expression in iERMs. (**A--D**) Because of the ERM folding, confocal microscopy shows ERM cells arranged in two rows and in a larger cluster, which is also the result of membrane folding. The left row is made of vimentin^+^/GFAP^−^ cells, the right row and the cluster (in the right superior corner of the figure) is formed by double-positive cells. The anti-TβRII antibody labels almost exclusively the left row of cells in the left inferior corner of the figure (vimentin^+^/GFAP^−^ cells). However, few vimentin/GFAP double-positive cells are also labeled (arrows). Cell nuclei were labeled with anti-histone H3 antibody. (**E-H**) Higher magnification of the lower region of the field shown in **A--D**. TβRII immunoreactivity is almost completely restricted to the vimentin^+^/GFAP^−^ cells on the left. (**I--L**) Confocal microscopy of cells expressing high levels of TβRII, which are also HSP90α/αSMA double-immunoreactive cells. *Arrows* point to the retinal side of the ILM, which is associated with the ERM. (**K**) Bright-field microscopy on a toluidine blue stained consecutive section of the same area shown in **I--L**. The ERM is associated with the ILM (*arrows* points to its retinal edge), which is also visible in **I** and **J** due to a very low level of background.](iovs-61-8-34-f002){#fig2}

TβRII^+^ Cells also Express HSP90α {#sec3-2}
----------------------------------

To further characterize ERM cells, we also stained sections with antibodies anti-HSP90α. HSP90α fluorescence could be detected with variable intensity in 75% of iERMs, being undetectable only in 4 samples out of 20. Triple labeling experiments showed that HSP90α colocalized with αSMA in TβRII^+^ cells ([Figs. 2](#fig2){ref-type="fig"}I--L).

HSP90α Immunoreactivity is Stronger in GFAP^−^ Cells and Type-I Collagen is Found within HSP90α^+^/Vimentin^+^/αSMA^+^ Cells {#sec3-3}
----------------------------------------------------------------------------------------------------------------------------

HSP90α immunoreactivity, however, was not restricted to just αSMA^+^ cells. Indeed, a signal for HSP90α, although fainter, could be observed also in GFAP^+^ cells ([Fig. 3](#fig3){ref-type="fig"}), which for the most part were αSMA^−^ cells ([Fig. 1](#fig1){ref-type="fig"}). Finally, to identify cells possibly involved in ERM collagen deposition, we carried out experiments to spot intracellular type-I collagen staining that could be observed in 41.7% of samples. Triple labeling experiments characterized these cells as vimentin^+^/αSMA^+^/HSP90α^+^ elements ([Figs. 4](#fig4){ref-type="fig"}A--H).

![(**A--C**) HSP90α differential expression in iERM. HSP90α expression does not appear uniform in cells of iERMs. Double labeling with GFAP shows that GFAP-expressing cells (*arrows*) contain less HSP90α than most GFAP^−^ cells.](iovs-61-8-34-f003){#fig3}

![Type-I collagen intracellular staining in iERM. (**A--D**) Type-I collagen can be found within vimentin^+^ cells lining a type-I and type-IV collagen immunoreactive membrane. Cells with type-I collagen intracellular staining have been highlighted. (**E--H**) Higher magnification on a second section from the same sample shown in **A--D**. In **E** and **G** some cells with type-I collagen intracellular staining have been circled or pointed at with an arrowhead. (**I--L**) Further analysis carried out on a third section from the same sample shown in **A--D** shows that type-I collagen containing cells are also HSP90α^+^/αSMA^+^ expressing cells. Cells with type-I collagen intracellular staining have been circled.](iovs-61-8-34-f004){#fig4}

HSP90 Enhances TGF-β1 Pathway Activation in Müller Glial Cells {#sec3-4}
--------------------------------------------------------------

To analyze the effect of HSP90 overexpression on TGF-β1 pathway in Müller glial cells, MIO-M1 cells were transduced with lentiviruses encoding for the human FLAG-tagged HSP90 or GFP (as control) ([Fig. 5](#fig5){ref-type="fig"}A) and treated with TGF-β1. In comparison to GFP-expressing cells, overexpression of HSP90 resulted in an increased basal level of SMAD2, SMAD3, and TGFβRII suggesting that, in Müller glial cells, HSP90 is involved in the stabilization of all these key elements of TGF-β1 transduction pathway. As a consequence of this, TGF-β1 treatment induced a higher rate of TGF-β1 pathway activation, as demonstrated by enhanced SMAD2 phosphorylation in HSP90 overexpressing cells ([Fig. 5](#fig5){ref-type="fig"}B).

![HSP90 enhances SMAD2, SMAD3, and TβRII expression and TGF-β1 pathway activation in Müller glial cells. (**A**) MIO-M1 Müller glia cells were transduced with lentiviruses encoding for the human FLAG-tagged HSP90 or GFP (as control). Transduction efficiency was monitored by fluorescence microscopy analysis of GFP expression in control cells. (**B**) Transduced cells were treated with human recombinant TGF-β1. Expression of endogenous SMAD2, SMAD3, and TGFβRII and transduced FLAG-tagged HSP90 were analyzed by immunoblot. TGF-β1 pathway activation was assayed using a specific phospho-SMAD2 (Ser465/467) antibody. The expression of β-actin was used as loading protein control.](iovs-61-8-34-f005){#fig5}

SMAD2 is Translocated to the Nucleus of iERM Cells {#sec3-5}
--------------------------------------------------

On the grounds of these results, to establish if the TGF-β1-induced transduction pathway was actually activated in vivo, we carried out additional immunofluorescence experiments on frozen sections of iERMs. Sections immunolabeled with anti-SMAD2 and anti-HSP90α antibodies showed both cytoplasmic and nuclear staining for SMAD2 either in HSP90α^+^ or HSP90α^−^ cells and some HSP90α^+^ cells that were devoid of SMAD2 nuclear labeling. At any rate, some HSP90α-expressing cells showed SMAD2 nuclear staining confirming that, at least in some cells, SMAD2 translocated to the nucleus ([Fig. 6](#fig6){ref-type="fig"}).

![SMAD2 translocation to the nucleus of iERM cells. Frozen sections were immunostained with anti-SMAD2 and anti-HSP90α antibody. Nuclei were counterstained with TO-PRO-3 iodide. Some HSP90α^+^ cells have only a faint SMAD2 cytoplasmic fluorescence (*large arrow*), some cells show only SMAD2 nuclear staining (*arrowheads*), and some HSP90α^+^ cells show SMAD2 cytoplasmic and nuclear staining (*small arrows*). SMAD2 nuclear staining indicates activation of the SMAD pathway.](iovs-61-8-34-f006){#fig6}

Discussion {#sec4}
==========

Patients affected by iERM may be asymptomatic or have serious visual impairment. In-between these two extreme conditions, a continuum of different degrees of severity can be observed.[@bib1] Only in the United States, approximately 30 million individuals are estimated to have at least one eye affected with an iERM.[@bib34] Idiopathic vitreoretinal proliferation (i.e., iERM) is therefore a major visual-threatening eye disorder, and any investigation that aids to shed some light on the physiopathology underlying its development may be important to devise new therapies or to perfect already existing treatments.

Bearing this in mind, we began our investigation to characterize cells in iERMs employing a novel approach, which has been previously applied to ERMs only once.[@bib22] In short, it consists of processing and embedding samples for electron microscopy and cutting 1-µm thick resin sections that were subsequently employed for immunofluorescence microscopy. The number of antibodies that can be used with this technique is higher than expected because of the recently devised improved heat-induced antigen retrieval procedures.[@bib35] We chose this approach as we wanted to carry out a large number of reactions on the same iERMs, which are notoriously very small samples.

We started using basic markers, such as intermediate filaments (vimentin and GFAP) and αSMA. Our results, being substantially in agreement with previous studies,[@bib7] confirm the reliability of the technique and show that two major populations of cells can be found in iERMs: one is formed by GFAP^+^/αSMA^−^ cells, the other by GFAP^−^/αSMA^+^ cells. A minor population of GFAP^+^/αSMA^+^ can also be observed but it consists of very few and scattered cells. In general, membranes with a majority of GFAP^+^ cells were poor in αSMA^+^ cells and, vice-versa, membranes with a majority of αSMA^+^ cells were poor in GFAP^+^ cells. However, virtually all cells express vimentin. These results suggest that a population of GFAP^+^/αSMA^−^ cells is capable of moving to the vitreoretinal interface and transdifferentiate toward an αSMA^+^ myofibroblast-like cell phenotype. The rarity of GFAP^+^/αSMA^+^ cells also suggests that once the cells start to transdifferentiate toward the αSMA^+^ myofibroblastic phenotype they rapidly lose GFAP. As GFAP in the retina is expressed only by astrocytes and, on activation, also by Müller cells,[@bib36] it is reasonable to hypothesize that most of the cells in iERMs may derive by one or both of these cell types. Actually, GFAP-immunoreactive Müller cells have been previously caught traversing the ILM and extending into ERMs.[@bib37]

It has been reported that iERMs contain cells expressing TβRII.[@bib7] This is significant as TGF-β seems to be an important player in several macular diseases. For instance, in addition to TGF-β1 in cells within iERMs,[@bib7] high levels of TGF-β2 have been also detected in the vitreous of patients affected by the same pathology and by neovascular age-related macular degeneration.[@bib38]^--^[@bib40]

However, a more detailed characterization of TβRII-expressing cells lacked. Here we have shown that TβRII-expressing cells are GFAP^−^/vimentin^+^/αSMA^+^ cells.

Considering that only few TβRII^+^ cells coexpress GFAP and vimentin, it is possible that these cells, such as GFAP^+^/αSMA^+^ cells, might represent glial cells in the early stages of transdifferentiation.

To further characterize TβRII^+^ cells, we have also shown that these cells express HSP90α and that TβRII^+^/HSP90α^+^/αSMA^+^ cells contain type-I collagen, suggesting that they are likely responsible for collagen deposition. Our experiments did demonstrate HSP90α in most but not all iERMs. This is probably because of the antibody employed in this study, which is specific for the alpha isoform of HSP90 that, in contrast to the constitutively expressed HSP90β, is an inducible isoform.[@bib41] Indeed, the inducible nature of HSP90α also explains why its expression does not appear uniform even within the same iERM, being usually less evident in GFAP^+^ cells.

HSP90α higher level of expression in TβRII^+^/αSMA^+^ cells prompted us to investigate its putative role in the development of the ERMs in vitro using the spontaneously immortalized Müller cell line MIO-M1. We chose this cell line as there is evidence that at least part of ERM cells may derive from Müller cells as previously reported.[@bib9] Our results show that HSP90 overexpression changes substantially TGF-β1-induced signal transduction pathway with an increased expression of TβRII^+^, SMAD2, and SMAD3 and with enhanced levels of SMAD2 phosphorylation. TGF-β1, previously reported in iERMs,[@bib7] can therefore activate SMAD2/3 intracellular transduction pathway more efficiently when cells express HSP90. It is well known that TGF-β1 is a profibrotic cytokine. It increases αSMA protein expression and type-I collagen synthesis by binding to TβRII and activating the SMAD pathway, which is crucial for tissue fibrosis.[@bib24] This pathway is partially quenched by Smurf-dependent TβRII ubiquitination, which directs the receptor to the proteasome system.[@bib42] As HSP90 is capable of protecting TβRII from proteasome degradation, it is also able to prolong TβRII phosphorylating activity, to maintain active the SMAD pathway and to increase TGF-β1 target gene expression.[@bib43] Thus HSP90 enhances the profibrotic weight of TGF-β1. Our finding that SMAD2 is translocated to the nucleus of HSP90^+^ even in vivo suggests that the well-established mechanisms underlying TGF-β1-induced matrix deposition in several fibrotic diseases[@bib44]^--^[@bib47] likely operate in iERMs as well. The use of Epon-embedded samples in this research has certainly reached the goal to allow us to make several different reactions on the same samples and gather more information from the same iERM. In addition, glutaraldehyde fixation and osmium post-fixation achieved a high level of tissue preservation unveiling many structural details that more conventional approaches could have missed. However, this technique has its drawbacks that also represent the limit of the present study. In particular, we could not use regular DNA dyes that do not work with such a strong fixation and on the harsh procedures required to deplasticize sections and to retrieve antigenicity (121°C). Moreover, although many antibodies have been successfully employed in this study, many others fail to bind their antigens in our setting despite that they are known to work with more conventional immunohistochemical approaches (i.e., formalin-fixed paraffin embedded samples). For instance, a convincing labeling of the ILM could not be achieved, although we tried several antibodies against the components of the membrane. Nevertheless, we could achieve a deeper characterization of αSMA^+^ myofibroblast-like cells that resulted in GFAP^−^/αSMA^+^/vimentin^+^/HSP90α^+^ and in almost half of the cases contained type-I collagen. The positive effects of HSP90 on the activation of the TGF-β1-induced SMAD-dependent transduction pathway has also been confirmed in vitro with HSP90-overexpressing MIO-M1 cells.

Because of the difficulties in collecting and processing ERMs, the number of samples we employed appears adequate for a study carried out mainly by immunofluorescence and confocal microscopy. However, more samples are needed to evaluate any correlation between the different cellular components and the clinical characteristics.

Conclusions {#sec5}
===========

Although more studies are needed, on the grounds of our observations we propose to consider HSP90 as a potential therapeutic target for iERMs

The authors thank G.A. Limb (Institute of Ophthalmology and Moorfields Eye Hospital) for providing the MIO-M1 cell line, and D. Orazioli for her excellent technical assistance.

Supported by MIUR (Ministero dell\'Istruzione, dell\'Università e della Ricerca) Grant "Dipartimento di eccellenza 2018-2022" to the Department of Biotechnology, Chemistry and Pharmacy, and by the I.Ri.Fo.R Onlus (Institute for the Research, Formation and Rehabilitation**)** Italian Union of Blind and Visually Impaired People.

Disclosure: **G.M. Tosi,** None; **M. Regoli,** None; **A. Altera,** None; **F. Galvagni,** None; **C. Arcuri,** None; **T. Bacci,** None; **I. Elia,** None; **G. Realini,** None; **M. Orlandini,** None; **E. Bertelli,** None

[^1]: GMT and MR equally contributed to the work.
